Cargando…

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia

Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects. This multicenter, randomized, open‐label study c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kario, Kazuomi, Nishizawa, Masafumi, Kiuchi, Mari, Kiyosue, Arihiro, Tomita, Fumishi, Ohtani, Hiroshi, Abe, Yasuhisa, Kuga, Hideyo, Miyazaki, Satoshi, Kasai, Takatoshi, Hongou, Makiko, Yasu, Takanori, Kuramochi, Jin, Fukumoto, Yoshihiro, Hoshide, Satoshi, Hisatome, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Hyperuricemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029836/ https://www.ncbi.nlm.nih.gov/pubmed/33400348 http://dx.doi.org/10.1111/jch.14153

Ejemplares similares

The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data
por: Akari, Seigo, et al.
Publicado: (2022)

Treatment for hyperuricemia and gout in Japan: Aspect of prescription and duration
por: Zhang, Di
Publicado: (2022)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
por: Fujishima, Yuya, et al.
Publicado: (2023)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Rationale, study design, and implementation of the ACS1 study: effect of azilsartan on circadian and sleep blood pressure as compared with amlodipine
por: Kario, Kazuomi, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
por: Nagai, Michiaki, et al.
Publicado: (2010)

Self‐measured worksite blood pressure and its association with organ damage in working adults: Japan Morning Surge Home Blood Pressure (J‐HOP) worksite study
por: Tomitani, Naoko, et al.
Publicado: (2020)

Association of lower nighttime diastolic blood pressure and hypoxia with silent myocardial injury: The Japan Morning Surge‐Home Blood Pressure study
por: Kubota, Kana, et al.
Publicado: (2020)

Digital Hypertension 2023: Concept, hypothesis, and new technology
por: Kario, Kazuomi, et al.
Publicado: (2022)

Cardiovascular Disease Prevention in Patients With Atherosclerotic Renovascular Disease‐Induced Resistant Hypertension: Further Considerations for 24‐Hour Blood Pressure Profiles
por: Narita, Keisuke, et al.
Publicado: (2022)

Changes in Blood Pressure Reactivity Against Physical Activity Evaluated by Multisensor-ABPM in Heart Failure Patients
por: Narita, Keisuke, et al.
Publicado: (2022)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

The Combination of Non-dipper Heart Rate and High Brain Natriuretic Peptide Predicts Cardiovascular Events: The Japan Morning Surge-Home Blood Pressure (J-HOP) Study
por: Ogoyama, Yukako, et al.
Publicado: (2020)

Different age‐related impacts of lean and obesity on cardiovascular prognosis in Japanese patients with cardiovascular risks: The J‐HOP (Japan Morning Surge‐Home Blood Pressure) Study
por: Toriumi, Shinichi, et al.
Publicado: (2021)

Atrial fibrillation is associated with cardiovascular events in obese Japanese with one or more cardiovascular risk factors: The Japan Morning Surge Home Blood Pressure (J‐HOP) Study
por: Watanabe, Hiroaki, et al.
Publicado: (2021)

Automatically assessed P‐wave predicts cardiac events independently of left atrial enlargement in patients with cardiovascular risks: The Japan Morning Surge‐Home Blood Pressure Study
por: Yokota, Ayako, et al.
Publicado: (2020)

Growth Differentiation Factor 15 Predicts Cancer Death in Patients With Cardiovascular Risk Factors: The J-HOP Study
por: Negishi, Keita, et al.
Publicado: (2021)

Impact of home blood pressure variability on cardiovascular outcome in patients with arterial stiffness: Results of the J‐HOP study
por: Ishiyama, Yusuke, et al.
Publicado: (2021)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Evaluation of the Effect of Topiroxostat on Renal Function in Patients with Hyperuricemia: STOP-C Study, a Retrospective Observational Cohort Study
por: Tamiya, Eiji, et al.
Publicado: (2022)

Seasonal Variation of Home Blood Pressure and Its Association With Target Organ Damage: The J-HOP Study (Japan Morning Surge-Home Blood Pressure)
por: Narita, Keisuke, et al.
Publicado: (2020)

Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure
por: Fujiwara, Takeshi, et al.
Publicado: (2021)

Growth Differentiation Factor‐15 Predicts Death and Stroke Event in Outpatients With Cardiovascular Risk Factors: The J‐HOP Study
por: Negishi, Keita, et al.
Publicado: (2021)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Tang, Yushang, et al.
Publicado: (2022)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

Short telomere length is associated with renal impairment in Japanese subjects with cardiovascular risk
por: Eguchi, Kazuo, et al.
Publicado: (2017)

Quantitative evaluation of white matter hyperintensities in patients with heart failure using an innovative magnetic resonance image analysis method: Association with disrupted circadian blood pressure variation
por: Komori, Takahiro, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Retracted: The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Healthcare Engineering, Journal of
Publicado: (2023)

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2014)

Differences in ambulatory blood pressure profiles between Japanese and Thai patients with hypertension /suspected hypertension
por: Tomitani, Naoko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p2tsal1famr3a9aujto8uohppm